Ceria Therapeutics Inc.
Tucson, AZ
- UEI
- STBNEMMGWMK3
- CAGE
- 8GDY1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- ceriatherapeutics.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Max Biopharma, Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Hillhurst Biopharmaceuticals, Inc. | Glendale, CA | — |
| Kevirx Inc. | Charlottesville, VA | — |
About the company
Ceria Therapeutics Inc. is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The company focuses on creating innovative treatments for conditions such as diabetic foot ulcers, acute lung injury, and acute respiratory distress syndrome (ARDS). Through federal grant awards, Ceria Therapeutics advances its patented technology combining cerium oxide nanoparticles with anti-inflammatory microRNA mimics to address unmet medical needs. The company's approach synergistically targets both inflammation and oxidative stress, which are central to the pathogenesis of various diseases and injuries.
Ceria Therapeutics has received multiple federal grant awards to support its research and development efforts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has funded the company's work on developing CTX-001 and CTX-004 for treating non-healing diabetic foot ulcers. These projects involve formulation development, preclinical efficacy studies, and preparation for IND-enabling studies. The National Heart Lung and Blood Institute (NHLBI) has supported the development of CTX-002 for treating acute lung injury and ARDS, including studies on pulmonary distribution, formulation optimization, and toxicology evaluations. Additionally, the Defense Health Agency has awarded Ceria Therapeutics a grant to advance a field-use therapeutic for pulmonary injuries resulting from trauma or chemical exposure. This work builds on the company's previous research and aims to prepare their novel therapeutics for first-in-human clinical trials.
Quick answers
Is Ceria Therapeutics Inc. registered in SAM.gov?
Yes. Ceria Therapeutics Inc.'s SAM.gov registration is active through January 22, 2027.
What is Ceria Therapeutics Inc.'s CAGE code?
Ceria Therapeutics Inc.'s CAGE code is 8GDY1, and its Unique Entity ID (UEI) is STBNEMMGWMK3.
What is Ceria Therapeutics Inc.'s most recent federal award?
Ceria Therapeutics Inc.'s most recent federal grant award is A novel anti-inflammatoryand anti-oxidant therapy for treating non-healing diabetic foot ulcers (R44DK136463), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on January 15, 2024.
On GovTribe
See Ceria Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors